Novavax's new COVID vaccine cleared for use by FDA

An updated COVID-19 vaccine made by Novavax has been authorized by the FDA, joining the two vaccines already cleared for use.

close up of a person's hand as they extract vaccine from a vial labeled "novavax"
Including the Novavax shot, there are now three updated COVID-19 vaccines available for 2023-2024.
(Image credit: JEROEN JUMELET / Contributor via Getty Images)

The Food and Drug Administration (FDA) has authorized a new formulation of the COVID-19 vaccine made by the Maryland-based pharmaceutical company Novavax, the agency announced Tuesday (Oct. 3). The newly updated "nanoparticle" vaccine joins the Pfizer and Moderna COVID-19 vaccines already cleared for use in the U.S.  

The Novavax shot now includes a spike protein — a pointy structure found on the virus's surface — from a version of the virus that is currently circulating, called XBB.1.5. The widespread subvariant branched off of the omicron family tree. Compared to its old formula, the new Novavax shot is expected to provide better protection against both XBB.1.5 and its close relatives that stem from the same branch. 

Nicoletta Lanese
Channel Editor, Health

Nicoletta Lanese is the health channel editor at Live Science and was previously a news editor and staff writer at the site. She is a recipient of the 2026 AHCJ International Health Study Fellowship, with a project focused on antibiotic stewardship practices in Japan and the U.S. They hold a graduate certificate in science communication from UC Santa Cruz and degrees in neuroscience and dance from the University of Florida. Beyond Live Science, Lanese's work has appeared in The Scientist, Science News, the Mercury News, Mongabay and Stanford Medicine Magazine, among other outlets. Based in NYC, she also remains involved in dance and performs in local choreographers' work.